DURHAM, N.C., July 31 (UPI) -- U.S. cancer researchers have discovered a two-drug combination that works better than either drug alone for patients with renal cell carcinoma."We found that by combining a drug that enlists the immune system’s help in combating cancer with one that cuts off a tumor’s blood supply, we could substantially increase patients’ response rates to treatment,” said Dr. Jared Gollob, who led the study with colleagues at the Duke University Comprehensive Cancer Center.
